The Research That Proves Long COVID is Not In Your Head

Welcome to Waves of Evidence, a monthly research roundup where I highlight and break down key Long COVID studies through the lens of a physical therapist specializing in Long COVID rehabilitation. Most features will focus on recent research, with occasional deep dives into foundational concepts. I hope you find it as fascinating as I do.

Publication Date: May 28, 2026

In Other Words: Your neurological symptoms from Long COVID are not all in your head. There’s a biological fingerprint.

• Researchers wanted to know whether elevated antibodies found in patients with Long COVID are causing neurological symptoms or if the antibodies are just coincidental. Prior research has identified unusual immune activity in Long COVID, but could not confirm whether those antibodies were driving the damage or just present alongside the neurological symptoms people were experiencing. This study was designed specifically to answer the following questions:

  • Could elevated autoantibodies be the main driver causing neurological symptoms like brain fog, headache, memory loss, dizziness, and pain in a certain subset of people with Long COVID?

  • Are there biomarkers that identify patients with autoantibody-driven Long COVID?

• Study design: This is a mechanistic laboratory study, which means it is designed to investigate how and why a biological, chemical, or physiological process works. The focus is on understanding cause and effect as opposed to evaluating the outcome of a specific intervention or treatment. In this study, the researchers purified immunoglobulin G antibodies (IgG antibodies) directly from the blood of patients with Long COVID, and then ran them through a series of experiments to explore the effects. In simpler terms…they took the antibodies (proteins from patients’ immune systems) and ran them through a series of tests. The tests included:

  • Applying IgG antibodies to human and mouse nervous tissue to see where they would react and bind.

    • Basically, they spread the antibodies onto brain and nerve tissue and observed what tissues the antibodies stuck to. This showed the researchers which part of the nervous system the antibodies were attracted to.

  • Screening IgG antibodies against a collection of 21,000-proteins to identify exactly what they were targeting.

    • They essentially held the antibodies up against a massive catalog of 21,000 different proteins to find their exact target. Think of it as if they were trying a key in thousands of locks to find the one(s) it opens.

  • Injecting antibodies into healthy mice to see whether the mice would develop the same neurological symptoms experienced by the human donors.

    • They took healthy mice, injected the patients' antibodies into them, and waited to see if the mice got sick in the same way the human patients did. This final step is called a passive transfer model, and it is the scientific gold standard for establishing causality rather than association.

• Study group: 55 Long COVID participants from the MY-LC cohort (the Mount Sinai–Yale Long COVID research database), selected specifically for having a high burden of neurological symptoms. The group was predominantly women, with an average age of 46.3 years. The most commonly reported symptoms were brain fog (80%), headache (65%), memory loss (64%), dizziness (58%), sleep disturbance (58%), and confusion (55%).

  • It is important to note that none of these participants had a prior autoimmune diagnosis. This ruled out the possibility that a pre-existing autoimmune condition was driving the symptoms or findings.

• The control group: Two comparison groups were included. The reason that this is important is because the two-tiered comparison allowed the researchers to isolate findings specific to Long COVID rather than COVID exposure in general.

  • Group 1: 42 convalescent controls (people who had COVID-19 but recovered fully without lingering symptoms)

  • Group 2: 39 healthy controls (people with no COVID history).

• Goal: To determine whether autoantibodies found in patients with Long COVID directly cause neurological symptoms, and to identify which specific proteins those antibodies are targeting.

• Findings: